For a patient with left cavitary pulmonary tuberculosis who developed severe hospital-acquired pneumonia treated with ceftazidime‑avibactam, now showing radiographic improvement but deteriorating after an upper gastrointestinal bleed and persistent leukocytosis, what management steps should be taken?

Continue Ceftazidime-Avibactam and Address the UGIB-Related Deterioration

For this patient with cavitary PTB and severe HAP showing radiographic improvement on ceftazidime-avibactam, the deterioration is most likely related to the UGIB complication rather than antibiotic failure, and treatment should continue while addressing the bleeding and monitoring closely for neutropenia.

Clinical Assessment Framework

The key question is whether deterioration represents:

1. HAP treatment failure (unlikely given CXR regression)
2. UGIB-related complications (most likely)
3. TB progression (requires evaluation)
4. Drug toxicity (must monitor)

Evidence Supporting Continued Antibiotic Therapy

The HAP is responding appropriately based on:

• Radiographic improvement after 7 days of therapy 1
• WBC trending down (21→18), indicating resolving infection
• Appropriate duration: HAP/VAP typically requires 7-8 days for uncomplicated cases 2, 3

In the HABP/VABP trial, ceftazidime-avibactam demonstrated non-inferior 28-day mortality (9.6% vs 8.3% for meropenem) with clinical cure rates of 67.2% 1. The drug showed efficacy against Enterobacteriaceae (69.2% cure) and P. aeruginosa (59.4% cure) 1.

Critical Management Steps

1. Continue Ceftazidime-Avibactam

• Complete 7-8 days minimum for HAP 2, 3
• The radiographic improvement indicates appropriate empiric coverage
• Stopping antibiotics prematurely risks treatment failure and mortality 2

2. Monitor for Drug-Induced Neutropenia (URGENT)

The WBC of 18 (down from 21) may represent:

• Normal infection resolution, OR
• Early ceftazidime-induced neutropenia (rare but serious)

Immediate actions:

• Check absolute neutrophil count (ANC) and differential NOW 4, 5
• If ANC <1.0 × 10⁹/L: Consider drug-induced agranulocytosis 4, 5
• If severe neutropenia develops: Discontinue ceftazidime-avibactam immediately and give G-CSF 4, 5
• Monitor CBC daily while on therapy 5

Ceftazidime-induced agranulocytosis can occur within 6-7 days of therapy, presenting as rapid neutrophil decline with bone marrow maturation arrest 5. Recovery typically occurs within 24-48 hours after drug cessation and G-CSF administration 4, 5.

3. Address UGIB Complications

The deterioration timing (after UGIB) suggests:

• Hemodynamic instability affecting organ perfusion
• Aspiration risk if massive bleeding occurred
• Anemia compromising oxygen delivery

Required evaluations:

• Hemoglobin/hematocrit trends
• Hemodynamic parameters (BP, HR, urine output)
• Repeat CXR to exclude aspiration pneumonia
• Endoscopy if not already performed

4. Reassess TB Treatment Status

For cavitary PTB, standard therapy is rifampin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampin/isoniazid for 4 months 6, 7.

Critical questions:

• Is patient on appropriate TB therapy?
• Was TB treatment interrupted during UGIB?
• Cavitary disease with positive cultures at 2 months requires 7-month continuation phase (total 9 months) 6

Pyrazinamide and liver disease: If UGIB caused by variceal bleeding (suggesting liver disease), monitor liver function closely 7. If AST/ALT >5× normal or bilirubin elevated, stop rifampin/isoniazid/pyrazinamide temporarily 7.

5. Obtain Microbiologic Data

• Sputum cultures (if not recent): Assess TB treatment response and identify HAP pathogens 2
• Blood cultures if febrile: Rule out bacteremia
• If cultures grow resistant organisms, adjust therapy accordingly 2

Duration of Antibiotic Therapy

For uncomplicated HAP with good clinical response: 7-8 days total 2, 3

Extend therapy if:

• Positive cultures after 3 months suggest treatment failure 6, 8
• Non-fermenting gram-negative bacilli (P. aeruginosa) may require longer duration 2, 3
• Clinical deterioration or persistent fever

Common Pitfalls to Avoid

1. Stopping antibiotics prematurely due to UGIB-related deterioration rather than HAP failure
2. Missing drug-induced neutropenia - monitor CBC daily 4, 5
3. Interrupting TB therapy during acute illness (increases resistance risk) 6
4. Attributing all deterioration to infection when UGIB complications (anemia, aspiration, hemodynamic instability) are likely culprits

If Neutropenia Develops

Immediate management:

• Stop ceftazidime-avibactam 4, 5
• Switch to alternative: cefoperazone-sulbactam or carbapenem (if susceptible) 5
• Administer G-CSF (filgrastim) 4, 5
• Expect neutrophil recovery within 24-48 hours 4, 5

Summary Algorithm

1. Check ANC immediately - if <1.0, stop ceftazidime-avibactam and give G-CSF
2. If ANC normal: Continue ceftazidime-avibactam to complete 7-8 days with daily CBC monitoring
3. Address UGIB: Stabilize hemodynamics, transfuse if needed, rule out aspiration
4. Verify TB therapy: Ensure appropriate regimen continues unless contraindicated by liver dysfunction
5. Obtain cultures: Guide de-escalation or adjustment if needed
6. Reassess at day 7-8: If improved, stop antibiotics; if not, investigate for resistant pathogens or alternative diagnoses